DE10223784A1 - Neue Formulierung zur parenteralen Applikation von Crobenetine - Google Patents
Neue Formulierung zur parenteralen Applikation von CrobenetineInfo
- Publication number
- DE10223784A1 DE10223784A1 DE10223784A DE10223784A DE10223784A1 DE 10223784 A1 DE10223784 A1 DE 10223784A1 DE 10223784 A DE10223784 A DE 10223784A DE 10223784 A DE10223784 A DE 10223784A DE 10223784 A1 DE10223784 A1 DE 10223784A1
- Authority
- DE
- Germany
- Prior art keywords
- pharmaceutical composition
- biii
- acetic acid
- composition according
- buffer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 8
- 238000007911 parenteral administration Methods 0.000 title claims description 3
- 238000009472 formulation Methods 0.000 title abstract description 5
- ILVITZMPXQQPBD-OFAXGOBFSA-N crobenetine Chemical compound O([C@H](CN1[C@@H]2CC3=CC=CC=C3[C@@H](C2(C)C)CC1)C)CC1=CC=CC=C1 ILVITZMPXQQPBD-OFAXGOBFSA-N 0.000 title 1
- 229950005056 crobenetine Drugs 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims abstract description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 61
- VCCBCXVFGHTDQN-UODBTFMRSA-N BIII-890CL Chemical compound O([C@H](CN1[C@@H]2CC3=C(O)C=CC=C3[C@](C2(C)C)(C)CC1)C)CC1=CC=CC=C1 VCCBCXVFGHTDQN-UODBTFMRSA-N 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 12
- 229930195725 Mannitol Natural products 0.000 claims description 12
- 239000008351 acetate buffer Substances 0.000 claims description 12
- 235000010355 mannitol Nutrition 0.000 claims description 12
- 239000000594 mannitol Substances 0.000 claims description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 7
- 239000000872 buffer Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims 3
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 1
- 235000017281 sodium acetate Nutrition 0.000 description 9
- 229940087562 sodium acetate trihydrate Drugs 0.000 description 9
- BDKLKNJTMLIAFE-UHFFFAOYSA-N 2-(3-fluorophenyl)-1,3-oxazole-4-carbaldehyde Chemical compound FC1=CC=CC(C=2OC=C(C=O)N=2)=C1 BDKLKNJTMLIAFE-UHFFFAOYSA-N 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 239000008215 water for injection Substances 0.000 description 7
- UWKTVIXWZRROOI-VLIWAZBPSA-N chembl2401795 Chemical compound Cl.O([C@H](CN1[C@@H]2CC3=C(O)C=CC=C3[C@](C2(C)C)(C)CC1)C)CC1=CC=CC=C1 UWKTVIXWZRROOI-VLIWAZBPSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000037396 body weight Effects 0.000 description 3
- 239000003978 infusion fluid Substances 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 206010014498 Embolic stroke Diseases 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- KDQPSPMLNJTZAL-UHFFFAOYSA-L disodium hydrogenphosphate dihydrate Chemical compound O.O.[Na+].[Na+].OP([O-])([O-])=O KDQPSPMLNJTZAL-UHFFFAOYSA-L 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 229940125794 sodium channel blocker Drugs 0.000 description 1
- 239000003195 sodium channel blocking agent Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10223784A DE10223784A1 (de) | 2002-05-29 | 2002-05-29 | Neue Formulierung zur parenteralen Applikation von Crobenetine |
| CA002487153A CA2487153A1 (en) | 2002-05-29 | 2003-05-23 | New formulation for the parenteral application of crobenetine |
| PCT/EP2003/005400 WO2003099280A1 (de) | 2002-05-29 | 2003-05-23 | Neue formulierung zur parenteralen applikation von crobenetine |
| JP2004506804A JP2005531573A (ja) | 2002-05-29 | 2003-05-23 | クロベネチンの非経口的用途用の新規製剤 |
| AU2003240699A AU2003240699A1 (en) | 2002-05-29 | 2003-05-23 | Novel formulation for the parenteral application of crobenetine |
| EP03730101A EP1511487A1 (de) | 2002-05-29 | 2003-05-23 | Neue formulierung zur parenteralen applikation von crobenetine |
| UY27824A UY27824A1 (es) | 2002-05-29 | 2003-05-27 | Nueva formulación para la administración parenteral de crobenetina. |
| PE2003000512A PE20040067A1 (es) | 2002-05-29 | 2003-05-27 | Nueva formulacion para la administracion parenteral de crobenetina |
| TW092114284A TW200406205A (en) | 2002-05-29 | 2003-05-27 | New formulation for the parenteral application of crobenetine |
| ARP030101864A AR040135A1 (es) | 2002-05-29 | 2003-05-28 | Nueva formulacion para la administracion parenteral de crobenetina (biii 890) |
| US10/446,613 US20040019075A1 (en) | 2002-05-29 | 2003-05-28 | New formulation for the parenteral application of crobenetine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10223784A DE10223784A1 (de) | 2002-05-29 | 2002-05-29 | Neue Formulierung zur parenteralen Applikation von Crobenetine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE10223784A1 true DE10223784A1 (de) | 2003-12-11 |
Family
ID=29432394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE10223784A Withdrawn DE10223784A1 (de) | 2002-05-29 | 2002-05-29 | Neue Formulierung zur parenteralen Applikation von Crobenetine |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1511487A1 (es) |
| JP (1) | JP2005531573A (es) |
| AR (1) | AR040135A1 (es) |
| AU (1) | AU2003240699A1 (es) |
| CA (1) | CA2487153A1 (es) |
| DE (1) | DE10223784A1 (es) |
| PE (1) | PE20040067A1 (es) |
| TW (1) | TW200406205A (es) |
| UY (1) | UY27824A1 (es) |
| WO (1) | WO2003099280A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10223783A1 (de) * | 2002-05-29 | 2003-12-11 | Boehringer Ingelheim Pharma | Neue Formulierung zur parenteralen Applikation eines Na-Kanal-Blockers |
-
2002
- 2002-05-29 DE DE10223784A patent/DE10223784A1/de not_active Withdrawn
-
2003
- 2003-05-23 AU AU2003240699A patent/AU2003240699A1/en not_active Abandoned
- 2003-05-23 WO PCT/EP2003/005400 patent/WO2003099280A1/de not_active Ceased
- 2003-05-23 CA CA002487153A patent/CA2487153A1/en not_active Abandoned
- 2003-05-23 EP EP03730101A patent/EP1511487A1/de not_active Withdrawn
- 2003-05-23 JP JP2004506804A patent/JP2005531573A/ja active Pending
- 2003-05-27 TW TW092114284A patent/TW200406205A/zh unknown
- 2003-05-27 PE PE2003000512A patent/PE20040067A1/es not_active Application Discontinuation
- 2003-05-27 UY UY27824A patent/UY27824A1/es not_active Application Discontinuation
- 2003-05-28 AR ARP030101864A patent/AR040135A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003099280A1 (de) | 2003-12-04 |
| AR040135A1 (es) | 2005-03-16 |
| EP1511487A1 (de) | 2005-03-09 |
| UY27824A1 (es) | 2003-12-31 |
| PE20040067A1 (es) | 2004-03-30 |
| CA2487153A1 (en) | 2003-12-04 |
| AU2003240699A1 (en) | 2003-12-12 |
| TW200406205A (en) | 2004-05-01 |
| JP2005531573A (ja) | 2005-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2513797C2 (de) | Pharmazeutische zusammensetzung | |
| DE68905096T2 (de) | Niacin und guar-mehl enthaltende zusammensetzung. | |
| DE69708284T2 (de) | Wässrige suspension von 9-hydroxyrisperidon-fettsäureester | |
| EP0357978B1 (de) | Pharmazeutische Zubereitung zur Behandlung des Diabetes mellitus | |
| DE69620393T2 (de) | PHARMAZEUTISCHE NICHTINORGANISCHE SALZLÖSUNGEN FÜR ENDONASALE VERABREICHUNG EINEs CALCITONINs | |
| DE2523998A1 (de) | Pharmazeutische zubereitung fuer die behandlung der schizophrenie | |
| WO2001010465A1 (de) | Moxifloxacin kochsalzformulierung | |
| DE4139017C2 (de) | Wäßrige Piroxicam-Lösungen und Verfahren zu ihrer Herstellung | |
| DE60103512T2 (de) | Pharmazeutische zusammensetzung enthaltend pemetrexed zusammen mit monothioglycerol, l-cystein oder thioglykolsäure | |
| EP1206244B1 (de) | Wässrige arzneimittelformulierung von moxifloxacin oder salzen davon | |
| DE69511448T2 (de) | Verwendung von Phosphorsäurediester-Verbindungen zur Unterdrückung von Krebsmetastasen in der Leber | |
| DE69424156T2 (de) | Arzneimittel zur prophylaxe und behandlung von katarakt | |
| DE60206871T2 (de) | Pharmazeutische Formulierung enhaltend Midazolam zur buccalen Verabreichung | |
| EP2040691B1 (de) | Wässrige arzneimittelformulierung von 4-[((4-carboxybutyl)-{2-[(4-phenethyl-benzyl)oxy]- phenethyl}amino)methyl]benzoesäure | |
| DE2448119C2 (de) | Pharmazeutische Zubereitung und Verfahren zur Herstellung der wäßrigen Form dieser Zubereitung | |
| EP1073469A1 (de) | Stabile mitoxantron-lösungen | |
| EP2001555A1 (de) | Verwendung von strobilurinen zur behandlung von störungen des eisen-stoffwechsels | |
| DE10223784A1 (de) | Neue Formulierung zur parenteralen Applikation von Crobenetine | |
| DE69922252T2 (de) | Parenterale lösungen enthaltend propofol (2,6-diisopropylphenol) und 2.5-di-0-methyl-1.4;3.6-dianhydro-d-glucitol als lösungsmittel | |
| DE602004012731T2 (de) | Zubereitungen mit verzögerter freigabe enthaltend zink, und herstellung derselben | |
| DE2314387C3 (de) | Arzneimittel zur Behandlung bösartiger Neubildungen | |
| DE60012183T2 (de) | Verwendung einer makrolid-verbindung zur herstellung eines medikaments zur behandlung von gehirnschäden aufgrund von ischämie oder blutungen | |
| DE69307197T2 (de) | Verwendung von 24,25-Dihydroxyvitamin-D3 zur Herstellung eines Arzneimittel zur Behandlung der Rachitis | |
| DE2401453A1 (de) | Pharmazeutische zusammensetzung zur behandlung von hautproliferationserkrankungen | |
| DE2723936A1 (de) | Ophthalmische loesung fuer die glaucom-behandlung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8139 | Disposal/non-payment of the annual fee |